The effects of body fluid biomarkers on neuropsychiatric disease

The effects of body fluid biomarkers on neuropsychiatric disease - Body fluid biomarkers in neuropsychiatric disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017795

Enrollment

360

Registered

2015-06-03

Start date

2015-06-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropsychiatric disease (mainly dementia)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Disease subjects: patients with neuropsychiatric disease (mainly dementia, e.g. Alzheimer's disease and Parkinson's disease with dementia). Controls: cognitively normal subjects.

Exclusion criteria

Exclusion criteria: Only the subjects in the neuroimaging study of PET/MRI/CT are included.

Design outcomes

Primary

Measure	Time frame
The association of the biomarkers observed in cerebrospinal fluid/blood with their clinical data and imaging data.	—

Secondary

Measure	Time frame
The clinical impact of the candidate biomarkers on the diagnosis of the neuropsychiatric disease.	—

Countries

Japan

Contacts

Public ContactHitoshi Shimada

National Institute of Radiological Science, Molecular Neuroimaging Center Molecular Neuroimaging Program

shimada@nirs.go.jp043-206-3251

Outcome results